Vesilute (ED)
ED Dipeptide | Bladder & Urinary Tract Bioregulator
Community Research
Join others researching Vesilute — share findings, ask questions, and learn from real experiences
Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium.
Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) enhance microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the urinary tract, (4) reduce hyperemia and inflammation-related dysfunction, and (5) modulate gene expression related to urogenital tissue homeostasis through bioregulation pathways characteristic of Khavinson peptides.
Molecular Data
E?Glutamic Acid
Position 1
Asp (ED)
Position 2
Research Indications
Research explores relief of symptoms associated with bladder dysfunction through smooth muscle regulation.
May support overall urinary tract function and tissue health.
Potential benefits for pelvic tissue health and function.
Research indicates potential to enhance blood flow and reduce dysfunction in prostate tissue.
May help alleviate symptoms associated with benign prostatic hyperplasia.
Part of comprehensive bioregulator protocols addressing age-related urogenital changes.
Supports cellular regeneration in urinary and reproductive tissues.
Dosing Protocols
Injectable form for subcutaneous or intramuscular administration. Standard Khavinson protocol of 10-20 day cycles, repeated 2-3 times per year for maintenance.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard protocol | 10-20 mg | Daily for 10-20 days | SubQ or IM |
| Maintenance | 20 mg | 2-3 cycles yearly | SubQ or IM |
Reconstitution Instructions
- Bacteriostatic water
- Insulin syringes
- Alcohol swabs
- Sterile vial
- 1 Clean work area thoroughly
- 2 Reconstitute with bacteriostatic water
- 3 Inject water slowly down vial wall
- 4 Gently swirl until dissolved
- 5 Store refrigerated at 2-8°C
- 6 Use within 4 weeks of reconstitution
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Generally well-tolerated
- Injection site reactions (mild, if injectable)
- Minimal reported side effects
Stop Signs - Discontinue if:
- Signs of allergic reaction
- Unusual urinary symptoms
- Unexpected changes in urination patterns
Contraindications
- Known hypersensitivity to peptide components
- Active urinary tract infection (treat first)
- Pregnancy or breastfeeding
- Prostate cancer (consult physician)
Quality Checklist
Good Signs
- White to off-white lyophilized powder
- Clear solution after reconstitution
- Certificate of analysis available
- Proper packaging and storage
Warning Signs
- Unknown source or unverified purity
Bad Signs
- Discolored powder
- Cloudy or particulate solution
- Damaged packaging
References
- Khavinson Bioregulator Peptides: Organ-Specific EffectsSt. Petersburg Institute of Bioregulation and Gerontology
Vesilute (ED dipeptide) targets bladder and urinary tract tissues with bioregulatory effects.
- Short Peptides and Urogenital FunctionRussian Medical Research
ED dipeptide influences smooth muscle and vascular function in urogenital tissues.
- Bioregulators in Anti-Aging MedicineKhavinson VKh et al.Advances in Gerontology
Organ-specific peptide bioregulators including Vesilute support tissue-specific regeneration.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.